CRTO reported Q1 2026 results this morning, delivering an earnings beat that failed to lift the stock above its recent range — and the tension between a clean headline print and a guarded revenue outlook defines the week.
Adj. EPS came in at $0.73, well ahead of the $0.56 consensus. Q1 sales reached $424.6 million, and the company disclosed a ChatGPT integration that drew immediate attention from ad-tech observers. But the enthusiasm cooled as management set Q2 contribution ex-TAC guidance of $260–264 million — a range that came in below expectations — and at least one analyst moved to a downgrade on the revenue trajectory. The stock rallied 4.5% on the day to $20.12, clawing back most of the month's losses, but coverage from Digiday and AdExchanger noted the shares had still given back ground from the open on the cautious forward guidance.
The lending market carries none of the urgency the headline numbers might suggest. Short interest is thin at roughly 2.1% of the float — a level that barely warrants a dedicated discussion — and availability in the borrow pool remains very loose. Cost to borrow has actually eased sharply over the past month, dropping more than 20% to around 1.1%, near the lowest readings in the trailing 30-day window. The ORTEX short score sits at 34, a benign reading that places CRTO near the middle of the distribution. Whatever the story is on this ticker this week, it is not a positioning squeeze.
Options sentiment has shifted slightly more defensive since late April, though not alarmingly so. The put/call ratio moved to 0.27, about 1.3 standard deviations above its 20-day average of 0.18. That shift, which began around April 22, likely reflects traders hedging into today's earnings rather than a structural change in view — and with the print now out, that protective posture may unwind. The 52-week PCR range of 0.07 to 1.08 keeps today's reading well inside normal territory.
The Street's stance leans constructive but has been drifting more cautious on valuation. Wells Fargo trimmed its target by $1 to $34 last week while keeping an Overweight rating, and Stifel made a similar small cut to $29 with a Buy maintained in mid-April. The mean price target at $28.86 implies roughly 43% upside from the current price — a wide gap that suggests either the Street has not fully rebased on the macro backdrop or the stock has further to recover from its multi-month de-rating. The EV/EBITDA multiple has nudged higher over the past month to around 2.1x, still exceptionally cheap for an ad-tech name, and the factor score on EV/EBIT ranks in the 94th percentile of the universe — signalling the market is pricing in continued pressure on earnings quality even as the headline beat today. EPS momentum scores in the 30- and 90-day windows remain below the median, reflecting the ongoing trend of lowered estimates across the Street.
Neuberger Berman held the largest institutional stake as of late February at nearly 16% of shares, and Norwegian manager DNB added roughly 1.2 million shares in a January filing. The insider picture shows Chairman Rik van der Kooi bought 5,000 shares in mid-March near $17.81 — a modest but directional signal from the boardroom — while the CFO and CLO ran routine plan-based sales around the same time.
The next catalyst now shifts to whether the ChatGPT partnership materialises into revenue in the Q2 print. Management's Q2 contribution ex-TAC guidance of $260–264 million is the line to watch; how that tracks against actual monetisation of the agentic AI ad integration will frame the narrative for the rest of 2026. Peers TTD and MGNI each rose around 5-6% on the week, suggesting the broader ad-tech tape was supportive — making CRTO's relative underperformance into guidance the more notable detail.
See the live data behind this article on ORTEX.
Open CRTO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
